HLA-A*01 Genotype Linked With Inferior Survival in Immune Checkpoint Inhibitor Setting Researchers determined an HLA-A*01 genotype has been linked with inferior OS and PFS among patients receiving immune checkpoint inhibitors.

Research presented at #ESMOTAT26 found that the human leukocyte antigen class 1 (HLA-A*01) genotype has been linked with inferior overall survival and progression-free survival among patients receiving immune checkpoint inhibitors.

bit.ly/4mo2zuz

@myesmo.bsky.social #HemOnc

Long-Term aHTA May Increase Risk for High-Grade CRS Researchers determined patients taking antihypertensive drugs for extended periods may be at elevated risk for high-grade CRS.

Patients #aHTA drugs for extended periods may be at elevated risk for high-grade #cytokineReleaseSyndrome.

https://bit.ly/4ce6ENs

#CRS #ESMOTAT26

👉 #ESMOTAT26 resources are now available!

Delegates and ESMO members can now access presentations, abstracts and session materials on #OncologyPRO.

🔗 Explore the materials: https://ow.ly/yNYq50Yvpl1

#ESMOMeetings

#ESMOTAT26: Semi-autonomous and autonomous agents and domain-specific foundation #AI models are helping transform #CancerResearch and clinical development according to Jorge Reis-Filho. Read the full Opinion piece in the #ESMODailyReporter: https://ow.ly/CQhL50YvHJW

#ESMOTAT26: As discussed by Nina Weisser in the #ESMODailyReporter, multispecifics offer huge potential but there are hurdles to overcome related to engineering, manufacturing, appropriate trial design and avoiding toxicity. Learn more ➡️ dailyreporter.esmo.org/esmo-targete...

#ESMOTAT26: Around half of patients treated with #TargetedTherapies according to ESCAT tier I and tier II survived for at least 12 months in early-phase ClinicalTrials within the 360 RESISTANCE study. Read more in the #ESMODailyReporter 📌 https://ow.ly/jIoQ50YvfMT

Novel agents targeting CD47-SIRPα alone or simultaneously with other mechanisms have the potential to promote antitumour efficacy as suggested by two phase I #ClinicalTrials presented at #ESMOTAT26. Read more details in the #ESMODailyReporter ➡️ https://ow.ly/VCt350YuNrT

🎉 Meet #ESMOMeritAward winners at #ESMOTAT26

🌟 ESMO is proud to support bright minds shaping the future of #CancerCare. Congratulations!

🔗https://ow.ly/2mTx50YuBNV

#CancerResearch #ESMOYOC #Oncology

#ESMOTAT26: In his interview in the #ESMODailyReporter, Timothy A. Yap, TAT Honorary Awardee, shares insights on innovative approaches to exploit synthetic lethality to ‘drug the undruggable’
📌https://ow.ly/FkSE50YuA7Q

#DrugDevelopment

#ESMOTAT26: Fostering academic #ClinicalResearch is one of the ESMO’s priorities, and #ArtificialIntelligence may be a major driver.
Read the Editorial by @fandremd.bsky.social in the #ESMODailyReporter ➡️ https://ow.ly/JYkz50YuzTr

⏰ Early registration for #ESMOTAT26 ends 28 Jan!
Join a leading multi-stakeholder forum on cancer #drugdiscovery in Paris.

🔗 Register now: https://ow.ly/VQce50XWy9H

#ESMOMeetings #targetedtherapies #PrecisionMedicine #ClinicalTrials

📣 Abstract submission is open for #ESMOTAT26
Showcase your research in #Cancer #DrugDiscovery & #TargetedTherapies.
Deadline: 16 December

🔗 Submit now: buff.ly/a4kXwWN